Qian Sun1, Hongyan Sun2, Lele Cong1, Yang Zheng1, Nan Wu1, Xianling Cong1. 1. Department of Dermatology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China. 2. Tissue Bank, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
We thank Chiavarini et al for his interest in our paper and for the opportunity to respond to his concerns.1 Chiavarini et al mainly pointed out in their letter that ten articles were not included in our meta-analysis. We read these ten articles in detail and answered them as follows:Botteri et al 2019.2 SIR was used as a risk measure in this study, and we did not find relevant method that could be used to convert SIR into OR/RR/HR, nor did we find evidence that could be combined with OR/RR/HR. In addition, the study only included women who were on hormone therapy and did not provide a control group of melanoma patients who were not on hormone therapy, so we do not think there is enough data to calculate RR. Finally, this article was excluded according to our exclusion criteria.Brinton et al 2015.3 This article evaluated OC, HRT, age at first birth, parity, and age at menarche, but the data associated with parity and age at menarche could not be combined due to different classification from those in our study. After we included this literature in the study, the re-obtained results showed that the combined risk of melanoma in OC users was 1.00 (0.90–1.10), I2=52%, among which the cohort study was 1.06 (0.98–1.14). The combined risk of melanoma in HRT users was 1.12 (1.02–1.23), I2=46%, among which the cohort study was 1.10 (1.02–1.19). Women aged 25–29 at first birth had a combined risk of 1.21 (0.89–1.63) and women aged ≥30 had a combined risk of 1.17 (0.74–1.87) for melanoma, compared with those aged < 25. These are consistent with the results and conclusions of our original paper.4Behrens et al 2010.5 This article looked at uveal melanoma, which was not included in our analysis and was therefore excluded.Vessey et al 2000.6 Vessey et al ‘s more complete data published in 2006 is cited in our article.7 The study population and data in the new paper include those in the old paper. The most recent and complete study was selected if studies from the same population were repeated, as stated in our inclusion and exclusion criteria.4Hannaford et al 1991.8 This article was excluded for the same reason as article 4. Hannaford et al ‘s more complete data published in 2007 is cited in our article.9 The study population and data in the new paper include those in the old paper.Holly et al 1991.10 This article looked at uveal melanoma, which was not included in our analysis and was therefore excluded.Hartge et al 1989.11 This article looked at eye melanoma, which was not included in our analysis and was therefore excluded.Gallagher et al 1986.12 Since the classification of the data in this paper is different from other literatures and cannot be combined, it is excluded because there is no available data.Green et al 1985.13 Since we could not find the full text of this literature, it was not included in the study.Kay et al 1981.14 We did not find this paper in the database.Thus, if Chiavarini et al had been careful enough, they would have found that nine of the ten articles should not have been included in the study. Although the second paper3 could be included, it did not significantly affect our results and conclusions.Concluding, our meta-analysis was methodologically rigorous enough that our conclusions were correct and indisputable.
Authors: Thomas Behrens; Linda Kaerlev; Ian Cree; Jean-Michel Lutz; Noemia Afonso; Mikael Eriksson; Pascal Guénel; Franco Merletti; Maria Morales-Suarez-Varela; Aivars Stengrevics; Svend Sabroe; Diane Cyr; Agustin Llopis-González; Giuseppe Gorini; Galina Sharkova; Lennart Hardell; Wolfgang Ahrens Journal: Cancer Causes Control Date: 2010-06-04 Impact factor: 2.506
Authors: Edoardo Botteri; Nathalie C Støer; Elisabete Weiderpass; Eero Pukkala; Olavi Ylikorkala; Heli Lyytinen Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-27 Impact factor: 4.254